HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis ; volume:19 ; number:1 ; day:5 ; month:12 ; year:2019 ; pages:1-9 ; date:12.2019
BMC cancer ; 19, Heft 1 (5.12.2019), 1-9, 12.2019
- Urheber
-
Albrecht, Thomas
Rausch, Melina
Rössler, Stephanie
Albrecht, Michael
Braun, Jana D.
Geissler, Veronika
Mehrabi, Arianeb
Vogel, Monika Nadja
Pathil-Warth, Anita
Mechtersheimer, Gunhild
Renner, Marcus
Rupp, Christian
Weiss, Karl Heinz
Busch, Elena
Köhler, Bruno Christian
Springfeld, Christoph
Schirmacher, Peter
Goeppert, Benjamin
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-019-6320-y
- URN
-
urn:nbn:de:101:1-2020040122380852348786
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Albrecht, Thomas
- Rausch, Melina
- Rössler, Stephanie
- Albrecht, Michael
- Braun, Jana D.
- Geissler, Veronika
- Mehrabi, Arianeb
- Vogel, Monika Nadja
- Pathil-Warth, Anita
- Mechtersheimer, Gunhild
- Renner, Marcus
- Rupp, Christian
- Weiss, Karl Heinz
- Busch, Elena
- Köhler, Bruno Christian
- Springfeld, Christoph
- Schirmacher, Peter
- Goeppert, Benjamin
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pathogenesis of human hepatocellular carcinoma
Pemigatinib : erste zielgerichtete Zweitlinientherapie beim Cholangiokarzinom mit FGFR2-Fusion/Rearrangement
Molecular diagnostics of hepatobiliary and pancreatic neoplasias
Opposite effects of tissue inhibitor of metalloproteinases-1 (TIMP-1) over-expression and knockdown on colorectal liver metastases
HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma
Expression of apoptosis repressor with caspase recruitment domain (ARC) in familial adenomatous polyposis (FAP) adenomas and its correlation with DNA mismatch repair proteins, p53, Bcl-2, COX-2 and beta-catenin
Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types
Estimating copy number using next-generation sequencing to determine ERBB2 amplification status
Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study
Is HER2 amplification predictable by digital immunohistochemistry?
Cardiac Melanoma Metastasis with ERBB2 Gene Amplification: A Potential for Future Targeted Therapy
Pathogenesis of human hepatocellular carcinoma
Pemigatinib : erste zielgerichtete Zweitlinientherapie beim Cholangiokarzinom mit FGFR2-Fusion/Rearrangement
Molecular diagnostics of hepatobiliary and pancreatic neoplasias
Opposite effects of tissue inhibitor of metalloproteinases-1 (TIMP-1) over-expression and knockdown on colorectal liver metastases
HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma
Expression of apoptosis repressor with caspase recruitment domain (ARC) in familial adenomatous polyposis (FAP) adenomas and its correlation with DNA mismatch repair proteins, p53, Bcl-2, COX-2 and beta-catenin
Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types
Estimating copy number using next-generation sequencing to determine ERBB2 amplification status
Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study
Is HER2 amplification predictable by digital immunohistochemistry?
Cardiac Melanoma Metastasis with ERBB2 Gene Amplification: A Potential for Future Targeted Therapy
Pathogenesis of human hepatocellular carcinoma
Pemigatinib : erste zielgerichtete Zweitlinientherapie beim Cholangiokarzinom mit FGFR2-Fusion/Rearrangement
Molecular diagnostics of hepatobiliary and pancreatic neoplasias
Opposite effects of tissue inhibitor of metalloproteinases-1 (TIMP-1) over-expression and knockdown on colorectal liver metastases
HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma
Expression of apoptosis repressor with caspase recruitment domain (ARC) in familial adenomatous polyposis (FAP) adenomas and its correlation with DNA mismatch repair proteins, p53, Bcl-2, COX-2 and beta-catenin
Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types
Estimating copy number using next-generation sequencing to determine ERBB2 amplification status
Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study
Is HER2 amplification predictable by digital immunohistochemistry?